Cambrex adds new development and analytical equipment in Italy

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/suprunvitaly)
(Image: Getty/suprunvitaly)

Related tags Active ingredient

Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.

According to the company, it has installed development and analytical equipment to support the development of highly potent APIs (HPAPIs), including a new 2,800-liter hydrogenator and 1,500mm diameter centrifuge.

Equipment installation and validation with be concluded by the end of 2017.

The small molecule and generic Active Pharmaceutical Ingredients (APIs) manufacturer opened the pilot plant in October 2016 at which time it said further upgrades would follow in order to support the production of Class 3/4 high potency products.

The cGMP plant can produce batch sizes from 1kg to 15kg.

Cambrex also invested $24m​ in a new Charles City, Iowa plant earlier this year. The facility is expected to be open in 2019.

The company’s High Point, NC-based facility was also expanded​ to include a new $3.2m, 11,000 square foot analytical laboratory in August. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Products

View more

Webinars